GRAIL, Inc.

GRAIL's Galleri® test is the only multi-cancer early detection blood draw test widely commercially available to patients today. Galleri® has the ability to detect a signal shared by over 50 cancers, 45+ of which do not have recommended screening tests currently available. Galleri® also detects the cancer signal of origin with 89% accuracy, all with a low (0.5%) false positive rate.

GRAIL is the only solution provider currently offering a comprehensive program to employers for the early detection of multiple cancers with a single blood draw. GRAIL's technology platform is developed based on a rigorous scientific approach to cancer biology and years of research. Our population-scale clinical study program is the largest of its kind, with over 300,000 participants and counting. For details about our clinical studies, publications, independent medical education, externally sponsored research, publications and more, please visit: https://grail.com/clinical-expertise/.